NCT03776357 is a NA clinical trial of VERA clinic in Total Joint Replacement Surgery, sponsored by Derek Amanatullah.

Who is sponsoring NCT03776357?

NCT03776357 is sponsored by Derek Amanatullah.

What drugs are being tested in NCT03776357?

Interventions in NCT03776357: VERA clinic.

What condition does NCT03776357 study?

NCT03776357 studies Total Joint Replacement Surgery.

Is NCT03776357 still recruiting?

NCT03776357 is currently terminated. Last updated 30 June 2022.

Are results published for NCT03776357?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-06-30 · How we verify

NCT03776357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement

Terminated NA Results posted Last updated 30 June 2022

What this trial tests

NA trial testing VERA clinic in Total Joint Replacement Surgery in 9 participants. Terminated before completion.

Timeline

26 August 2019

Primary endpoint
10 March 2020

10 March 2020

Quick facts

Lead sponsor	Derek Amanatullah
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	9
Start date	26 August 2019
Primary completion	10 March 2020
Estimated completion	10 March 2020
Sites	1 location across United States

Drugs / interventions tested

VERA clinic

Conditions studied

Total Joint Replacement Surgery — all drugs for Total Joint Replacement Surgery →

Sponsor

Derek Amanatullah

Who can join

Adults 18 to 99, any sex, with Total Joint Replacement Surgery. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Length of Stay in Hospital Through Discharge Primary · Up to 2 days

Group	Value	95% CI
Experimental	2	2 – 2

Number of Participants Requiring Gait Aid Use Secondary · 3 months post operative visit

The gait aide use ranges in the order of decreasing performance as Nothing \> Cane \> crutch \> walker.

None ( no gait aide)

Group	Value	95% CI
Experimental	9

Cane

Group	Value	95% CI
Experimental	0

Crutch

Group	Value	95% CI
Experimental	0

Walker

Group	Value	95% CI
Experimental	0

Knee Society Score (KSS) Secondary · 3 months post operative visit

To assess the effectiveness of the device by calculating knee society score (KSS) after surgery. The scale ranges from 0-100 with grading as Score 80-100 - Excellent Score 70-79 - Good Score 60-69 - Fair Score below 60 - Poor

Excellent (80-100)

Group	Value	95% CI
Experimental	6

Good (70-79)

Group	Value	95% CI
Experimental	0

Fair (60-69)

Group	Value	95% CI
Experimental	2

Poor ( below 60)

Group	Value	95% CI
Experimental	1

Knee Range of Motion Secondary · 3 months post operative visit

To assess the effectiveness of the device by calculating range of motion (maximum degrees)

extension

Group	Value	95% CI
Experimental	1.1	± 2.2

flexion

Group	Value	95% CI
Experimental	107.8	± 17.5

Sponsor's own description

This is the research study of a rehabilitation tool that informs, guides and empowers clinicians to care for their patients. We hope to learn ways to improve patient outcomes, reduce costs and increase value to the healthcare system

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Derek Amanatullah trials

Trials by the same sponsor.

NCT03777007 — A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03776357 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Derek Amanatullah
Last refreshed: 30 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03776357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing